June 13, 2016
During the Monday morning plenary at the 2016 SNMMI Annual Meeting, the Michael J. Fox Foundation (MJFF) announced a $2 million prize for development of a PET tracer to visualize the protein alpha-synuclein, the priority therapeutic target and biomarker candidate of Parkinson’s disease research. The prize aims to motivate the field toward this vital research tool, which would allow for earlier and more precise diagnosis, progression tracking, and more efficient and effective intervention testing.
“The ability to image alpha-synuclein in the brain would be a game-changer for Parkinson’s translational research and would rapidly accelerate testing of therapies to slow or stop disease progression,” said Jamie Eberling, PhD, MJFF director of research programs, who announced the prize.
The Foundation has created a website with detailed contest rules, criteria for winning, timeline and submission requirements.
“This not only attests to the importance of molecular brain imaging in Parkinson’s disease, it also makes scientists so excited about making alpha synuclein imaging possible in humans," said Satoshi Minoshima, MD, PhD, chair of SNMMI's Scientific Program Committee. "I would like to sincerely thank the Michael J. Fox Foundation.”